COMMUNIQUÉS West-GlobeNewswire

Theratechnologies’ CFO to Attend 39ᵗʰ Annual Growth Conference Held by Canaccord Genuity in Boston

05/08/2019 - 13:30

MONTREAL, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that Philippe Dubuc, Senior Vice President and Chief Financial Officer, will attend the 39 th [...]

Le chef de la direction financière de Theratechnologies assistera à la 39ᵉ Annual Growth Conference tenue par Canaccord Genuity à Boston

05/08/2019 - 13:30

MONTRÉAL, 05 août 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) est heureuse d’annoncer que Philippe Dubuc, vice-président sénior et chef de la direction financière assistera à la 39 e [...]

Arbutus Reports Second Quarter 2019 Financial Results and Provides Corporate Update

05/08/2019 - 13:30

- Appointed William Collier , with decades of leadership experience in antivirals, President & CEO - Announced preliminary Phase 1a/1b clinical trial results demonstrating that AB-506 is a potent capsid inhibitor in [...]

BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

05/08/2019 - 13:15

RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted six newly-hired [...]

Allakos Reports Second Quarter 2019 Financial Results

05/08/2019 - 13:15

REDWOOD CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today [...]

The Joint Corp. Increases Corporate Clinic Portfolio by Two, to Reach 57

05/08/2019 - 13:05

Acquires Clinic in South Carolina Market, Expanding New Corporate Market Opens Greenfield in El Cajon, Broadening the San Diego Portfolio SCOTTSDALE, Ariz., Aug. 05, 2019 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: [...]

Altimmune to Announce Second Quarter 2019 Financial Results on August 14

05/08/2019 - 13:00

GAITHERSBURG, Md., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies, today announced that it [...]

FH Ortho Receives Regulatory Clearance in Japan for its Arrow® Prime Anatomic Shoulder System

05/08/2019 - 13:00

MULHOUSE, France, Aug. 05, 2019 (GLOBE NEWSWIRE) -- FH Ortho, a manufacturer of orthopedic devices and instruments for surgeons around the world, announced it has received approval from the Pharmaceuticals and Medical [...]

Invitation: Terveystalo H1 Result – Webcast and Conference Call on 8 August 2019

05/08/2019 - 13:00

Terveystalo Plc will publish its half-year report for 2019 on 8 August at 9:00 EEST. (Finnish time). Materials are available after publication at: https://www.terveystalo.com/en/investors/Financial-information/ [...]

Allakos Announces AK002 Met All Prespecified Primary and Secondary Endpoints in Phase 2 Randomized, Double-Blind, Placebo-Controlled Study in Patients with Eosinophilic Gastritis (EG) and/or Eosinophilic Gastroenteritis (EGE)

05/08/2019 - 13:00

Primary efficacy endpoint met with 95% reduction in gastrointestinal tissue eosinophils vs. 10% increase on placebo (p < 0.0001) Treatment response secondary endpoint met with 69% of AK002 treated patients meeting [...]

Arvinas Reports Second Quarter 2019 Financial Results and Provides Corporate Update

05/08/2019 - 13:00

NEW HAVEN, Conn., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the [...]

CADScor®System – Significantly more effective than current practice

05/08/2019 - 12:30

Press release Malmö August 5, 2019 CADScor®System – Significantly more effective than current practice Acarix AB (publ) (ACARIX: FN Stockholm) today announced the publication of a meta-analysis including 2245 patients [...]

Quotient Limited Provides Updates on European Hypercare Launch, the CE Mark Submission and U.S. Field Trial for the Initial Serological Disease Screening Microarray, and Reports First Quarter Fiscal 2020 Results

05/08/2019 - 12:15

First European hypercare launch site initiated following CE mark approval Initial Serological Disease Screening microarray submitted for CE marking U.S. field trial activities for initial Serological Disease Screening [...]

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2019

05/08/2019 - 12:00

RANCHO CUCAMONGA, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its second quarter of 2019 ended June 30, 2019, after the [...]

Allogene Therapeutics Appoints Rafael G. Amado, M.D. as Executive Vice President of Research and Development and Chief Medical Officer

05/08/2019 - 12:00

Dr. Amado’s Addition to the Senior Leadership Team Reunites Him with Former Colleagues in the Pursuit of Novel Immunotherapies SOUTH SAN FRANCISCO, Calif, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. ( [...]

Nexstim NBT® system authorized for commercial distribution in Australia

05/08/2019 - 12:00

Press release, Helsinki, 5 August 2019 at 1 pm (EET) Nexstim NBT ® system authorized for commercial distribution in Australia Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") - the targeted neuromodulation [...]

Share buy-back week 31/2019

05/08/2019 - 11:04

Announcement 5 August 2019 Coloplast – transactions in connection with share buy-back programme As mentioned in Announcement No. 2/2019 Coloplast has initiated the second part of the share buy-back programme totalling [...]

Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD

05/08/2019 - 08:00

LONDON, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces positive Phase 2 data with a dry powder [...]

AB Science provides an update on its masitinib clinical program

05/08/2019 - 07:31

Paris, August 5 2019, 7.30am Update on masitinib clinical program AB Science SA (NYSE Euronext - FR0010557264 - AB) provides an update on its masitinib clinical program. The key points of the masitinib clinical program [...]